Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
Public ClinicalTrials.gov record NCT01100658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effects of Methylphenidate on Neuropsychological Functioning in Children With Attention Deficits Secondary to Childhood Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion.
Study identification
- NCT ID
- NCT01100658
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 1 participant
Conditions and interventions
Conditions
- ALL, Childhood
- Leukemia, Lymphoblastic
- Leukemia, Lymphoblastic, Acute
- Leukemia, Lymphoblastic, Acute, L1
- Leukemia, Lymphoblastic, Acute, L2
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
- Leukemia, Lymphocytic, Acute
- Leukemia, Lymphocytic, Acute, L1
- Leukemia, Lymphocytic, Acute, L2
- Lymphoblastic Leukemia
- Lymphoblastic Leukemia, Acute
- Lymphoblastic Leukemia, Acute, Childhood
- Lymphoblastic Leukemia, Acute, L1
- Lymphoblastic Leukemia, Acute, L2
- Lymphoblastic Lymphoma
- Lymphocytic Leukemia, Acute
- Lymphocytic Leukemia, L1
- Lymphocytic Leukemia, L2
- Brain Tumors
- Cancer of the Brain
- Cancer of Brain
- Malignant Primary Brain Tumors
- Brain Neoplasms, Malignant
Eligibility (public fields only)
- Age range
- 8 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- Mar 26, 2015
2010
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Minnesota Medical Center, Fairview | Minneapolis | Minnesota | 55455 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01100658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2015 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01100658 live on ClinicalTrials.gov.